Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rose 2.99% on Wednesday, closing at $135.86, outperforming the broader market indexes like the S&P 500 and Dow Jones Industrial Average. This increase ended a three-day losing streak for the company's shares. The positive performance occurred during an overall strong trading session for the stock market.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) stock fell 2.99% on Monday, closing at $133.07, and underperformed major indices like the S&P 500 and Dow Jones Industrial Average, which also saw declines. This marks the second consecutive day of losses for the company's stock.
Will Teleflex’s (TFX) Lowered 2026 Earnings Guidance and Margin Pressures Redefine Its Portfolio Story?
Teleflex reported Q2 2026 results with higher sales but lower net income, topping revenue and non-GAAP earnings expectations while cutting its 2026 earnings guidance. The lowered guidance, coupled with integration and margin pressures, challenges the investment narrative built around acquisitions and portfolio optimization. Investors are now focused on whether integration progress and cost discipline can become a near-term earnings catalyst for the company.
311,349 Shares in Teleflex Incorporated $TFX Purchased by Diamond Hill Capital Management LLC Investment Advisor
Diamond Hill Capital Management LLC purchased 311,349 shares of Teleflex Incorporated (NYSE:TFX) in Q2, valued at approximately $39.5 million, giving them a 0.70% stake. Teleflex exceeded Q2 earnings expectations, reporting $1.76 EPS against a $1.28 consensus and revenues of $570.3 million, a 28.9% year-over-year increase, and has forecasted fiscal 2026 EPS between $6.90 and $7.20. Despite a consensus "Hold" rating from analysts, other institutional investors have also adjusted their holdings in the medical technology company.
Teleflex Incorporated (NYSE:TFX) Receives Average Rating of "Hold" from Analysts
Teleflex Incorporated (NYSE:TFX) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $151.80. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and provided fiscal 2026 EPS guidance of $6.90 to $7.20. Institutional investors own a significant portion of Teleflex's shares, and the company maintains a quarterly dividend of $0.34 per share.
Assenagon Asset Management S.A. Invests $1.39 Million in Teleflex Incorporated $TFX
Assenagon Asset Management S.A. has acquired 10,974 shares of Teleflex Incorporated (NYSE:TFX), valued at approximately $1.39 million, making it a new position for the firm in the second quarter. Teleflex has shown strong financial performance, exceeding quarterly earnings expectations with an EPS of $1.76 and revenue of $570.33 million, a 28.9% increase year-over-year. The company maintains a consensus "Hold" rating from analysts with an average price target of $151.80 and recently announced a quarterly dividend of $0.34 per share.
Teleflex (TFX) Stock Looks Undervalued On Cash Flow But Overvalued On Sales
Teleflex (TFX) stock appears undervalued based on a Discounted Cash Flow (DCF) model, suggesting a 46.8% discount from its intrinsic value due to strong free cash flow and planned debt reduction and buybacks. However, the stock screens as overvalued on a Price/Sales (P/S) multiple compared to its fair ratio implied by fundamentals, despite being below the wider industry benchmarks. This mixed valuation highlights a discrepancy between its cash flow generation potential and market multiples, leaving its future direction dependent on successful execution of portfolio plans and cash generation.
Teleflex (TFX) Q2 2026 Earnings Call Transcript
Teleflex reported a 4.7% increase in pro forma adjusted constant currency revenue for Q2 2026, driven by strong Vascular and Surgical segment performance, despite Interventional segment integration challenges. The company completed a $1.5 billion OEM divestiture to fund debt reduction and share repurchases, and it raised its full-year adjusted EPS guidance due to lower interest expenses and share buybacks. Teleflex also highlighted the FDA approval of EZPLAZ and advancements in its Freesolve clinical trials, emphasizing a strategic shift toward core critical care and high-acuity markets.
First Trust Advisors LP Reduces Stock Position in Teleflex Incorporated $TFX
First Trust Advisors LP significantly reduced its stake in Teleflex Incorporated by 98.4% in Q1 2026, selling over 161,000 shares but retaining a small position. Despite this, institutional investors still hold a substantial 95.62% of the company's stock. Teleflex reported strong Q2 earnings, beating analyst estimates, and announced a quarterly dividend.
Teleflex Inc. stock outperforms competitors on strong trading day
Shares of Teleflex Inc. (TFX) increased by 2.08% to $136.32 on Wednesday, marking its second consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average fell by 0.04%.
Bank of America Corp DE Buys 27,004 Shares of Teleflex Incorporated $TFX
Bank of America Corp DE increased its stake in Teleflex Incorporated by 6.4% in the first quarter, acquiring an additional 27,004 shares, bringing its total holdings to 445,958 shares valued at $53.3 million. Institutional investors collectively own 95.62% of Teleflex. The company exceeded its quarterly earnings expectations with $1.76 EPS and $570.33 million in revenue, and analysts currently maintain a consensus "Hold" rating with an average price target of $151.80.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) stock declined by 1.47% on Monday, closing at $133.00, despite a generally poor trading session for the broader market. This marks the second consecutive day of losses for the company. The S&P 500 Index (SPX) fell 0.06% and the Dow Jones Industrial Average (DJIA) fell 0.11% on the same day.
TELEFLEX INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $150 FROM $143
Truist Securities has increased its target price for Teleflex Incorporated (TFX.N) to $150 from $143. This update indicates a more positive outlook from the securities firm on the medical technology company's stock. The information was reported by Reuters.
Truist Securities Adjusts Price Target on Teleflex to $150 From $143, Keeps Hold Rating
Truist Securities has increased its price target for Teleflex (NYSE:TFX) to $150 from $143, while maintaining a "Hold" rating on the stock. This adjustment comes amidst other analyst activities, including RBC Capital Markets' assessment that Teleflex's 2027 framework is achievable and Needham raising its price target to $159. Teleflex recently reported its Q2 2026 earnings, showing an increase in adjusted EPS and revenue, and updated its full-year 2026 earnings guidance.
Teleflex Incorporated (TFX) Stock Analysis: Exploring a Promising 11.67% Upside Potential in the Healthcare Sector
Teleflex Incorporated (TFX) is a significant player in the healthcare sector, providing single-use medical devices, and analysts see an 11.67% upside potential for the stock. Despite robust revenue growth, the company faces challenges with negative EPS and a high dividend payout ratio, which investors should consider. Technical indicators suggest bullish momentum, trading above key moving averages, but a high RSI hints at potentially overbought conditions.
Teleflex Q2 Earnings Call Highlights
Teleflex reported Q2 revenue and adjusted earnings above expectations, driven by strong Vascular and Surgical business growth. However, the slower-than-anticipated integration of its Vascular Intervention acquisition impacted Interventional results. The company outlined plans for divestitures, debt reduction, and share repurchases, and updated its full-year 2026 outlook, lowering revenue growth but raising EPS guidance.
Teleflex Inc.: Entered Accelerated Share Repurchase Program With Truist Bank >TFX
Teleflex Inc. has announced that it has entered into an accelerated share repurchase program with Truist Bank. This program allows Teleflex to repurchase its own shares, typically indicating management's belief that the stock is undervalued.
Teleflex Incorporated (TFX) Stock Forecasts
Argus has raised its target price for Teleflex Incorporated (TFX) to $147.00. Teleflex, a manufacturer of hospital supplies and medical devices, is currently priced at $134.98. The report provides a summary of the company's operations and offers insights for potential investors.
Teleflex Inc.: To Repurchase Aggregate $250M of Co's Common Stock>TFX
Teleflex Inc. announced its intention to repurchase an aggregate of $250 million of its common stock. This move is typically seen as a way for a company to return value to shareholders and can indicate management's confidence in the company's future prospects. The repurchase program could impact the company's stock price and financial metrics.
Teleflex Inc. stock underperforms Friday when compared to competitors
Teleflex Inc. (TFX) shares dropped 2.82% on Friday, closing at $134.98, despite a positive trading day for the broader market with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is currently 6.91% below its 52-week high of $145.00, which was reached on August 6th.
Amundi Has $4.62 Million Stake in Teleflex Incorporated $TFX
Amundi increased its stake in Teleflex Incorporated (NYSE:TFX) by 325.2% in the first quarter, now holding 38,606 shares valued at approximately $4.62 million. Teleflex exceeded second-quarter expectations with adjusted EPS of $1.76 and revenue of $570.3 million, and raised its fiscal 2026 EPS guidance to $6.90–$7.20. Despite strong adjusted results and a declared quarterly dividend of $0.34 per share, GAAP EPS and net margin remained weak, leading analysts to maintain a "Hold" rating with a consensus price target of $148.90.
Teleflex Medical OEM relaunches as INGENYX
INGENYX, formerly Teleflex Medical OEM, has launched as an independent company after being acquired by Montagu and Kohlberg and carved out from Teleflex Inc. The company specializes in developing and manufacturing custom-engineered interventional catheters, sutures, and other advanced medical device technologies. This move positions INGENYX to expand its capabilities, accelerate innovation, and strengthen customer collaboration in the medical device manufacturing sector.
Teleflex Incorporated Announces Quarterly Dividend of $0.34 (NYSE:TFX)
Teleflex Incorporated (NYSE:TFX) announced a quarterly dividend of $0.34 per share, payable on September 30th to shareholders of record on August 14th. This represents an annualized dividend of $1.36, yielding 1.0%, and is well-covered by earnings with a payout ratio of 9.7%. The medical technology company also reported strong quarterly adjusted EPS of $1.76, surpassing estimates, and a 28.9% year-over-year revenue increase to $570.33 million.
Teleflex Inc 2Q 2026: Revenue $570.33M, EPS $2.28— 10-Q Summary
Teleflex Inc. reported its second-quarter 2026 results, with revenue increasing to $570.33 million, a 28.9% rise year-over-year, largely due to the acquired VI Business and increased product volumes. However, diluted EPS fell to $2.28 from $2.77, and net income decreased by 18.7%. The company is undergoing significant strategic changes, including shifting to direct sales channels, divesting certain product lines, and integrating the BIOTRONIK VI business to expand its interventional portfolio, alongside implementing cost-reduction measures and addressing supply-chain and geopolitical risks.
Teleflex Inc (TFX) (Q2 2026) Earnings Call Highlights: Strong Core Performance Offset by VI ...
Teleflex Inc (TFX) reported better-than-expected Q2 2026 revenue, adjusted margins, and EPS, driven by strong vascular and surgical performance and significant proceeds from an OEM divestiture. However, the company reduced its 2026 pro forma adjusted constant currency revenue growth guidance due to slower-than-expected integration of the vascular intervention (VI) business, impacting interventional revenue and operating margins. Despite these integration challenges, Teleflex remains committed to shareholder returns through repurchases and expects a significant step-up in financial performance in 2027.
Teleflex Q2 2026 slides: mixed results amid integration challenges
Teleflex reported mixed Q2 2026 results with strong performance in Vascular and Surgical segments, but challenges in integrating its Interventional business led to a reduced revenue outlook. Despite lower revenue guidance, the company raised its adjusted EPS guidance due to share repurchases and lower interest expense. Teleflex is undergoing strategic transformation, including a major divestiture and significant capital return to shareholders, while making progress on innovative products like EZPLAZ™ and its Resorbable Magnesium Scaffold.
Earnings Flash (TFX) Teleflex Incorporated Reports Q2 Revenue $570.3M, Vs. FactSet Est of $559.6M
Teleflex Incorporated (TFX) reported its second-quarter revenue, reaching $570.3 million. This figure exceeded FactSet's estimated revenue of $559.6 million. The announcement provides key financial data for investors and market analysts.
Quantinno Capital Management LP Sells 23,263 Shares of Teleflex Incorporated $TFX
Quantinno Capital Management LP reduced its stake in Teleflex Incorporated by 30.2% in the first quarter, selling 23,263 shares and retaining 53,766 shares valued at approximately $6.4 million. Despite mixed analyst ratings, with an overall "Hold" consensus and an average price target of $148.90, Teleflex exceeded quarterly expectations, reporting $1.39 EPS and $548.3 million in revenue. The company also declared a $0.34 quarterly dividend, contributing to an annualized payout of $1.36 and a yield of about 1.0%.
Teleflex Closes $1.5B OEM Sale; Business Rebrands as Ingenyx
Teleflex has completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, with net proceeds estimated at $1.25 billion. The OEM business will now operate independently under the new brand Ingenyx, aiming to accelerate innovation and expand its services beyond traditional contract manufacturing. This strategic move allows Teleflex to focus on its remaining businesses while Ingenyx gains dedicated resources and private equity backing to invest in its growth and capabilities in medical device development and manufacturing.
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
INGENYX, formerly Teleflex Medical OEM, has launched as an independent company after its acquisition by Montagu and Kohlberg. The company aims to accelerate innovation in the MedTech industry by expanding engineering capabilities and strengthening customer collaboration, building on over 40 years of experience in custom-engineered medical device technologies. INGENYX will focus on helping medical device manufacturers navigate complex product development, material selection, and commercialization challenges.
Teleflex stock hits 52-week high at $139.77
Teleflex Inc. (TFX) stock has reached a new 52-week high of $139.77, reflecting a 34% surge over the past six months and a 19.24% increase over the last year. InvestingPro analysis indicates the stock is currently undervalued, and the company has consistently paid dividends for 50 years. Recent developments include FDA approval for its EZPLAZ Freeze Dried Plasma, increased price targets from analysts, and the issuance of $500 million in senior notes.
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Teleflex Incorporated announced the completion of the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. This strategic move aims to sharpen Teleflex's focus on commercial excellence, enhance financial flexibility, and support its growth strategy through debt reduction and share repurchases. Teleflex expects approximately $1.25 billion in after-tax proceeds and plans to update its 2026 financial guidance.
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Teleflex Incorporated has completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. This strategic move sharpens Teleflex's focus on its core commercial businesses and enhances financial flexibility. The company plans to use the net proceeds, estimated at $1.25 billion after tax, to reduce debt by $800 million and complete its $1 billion share repurchase authorization.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 2.19% to $139.70 on Monday, outperforming the broader market. This marked the stock's second consecutive day of gains, as the S&P 500 Index and Dow Jones Industrial Average also saw significant increases.
How FDA Approval of First Freeze Dried Plasma Platform Will Impact Teleflex (TFX) Investors
Teleflex (TFX) recently received FDA approval for EZPLAZ Freeze Dried Plasma, the first FDA-licensed freeze-dried plasma for adult transfusions, which could reshape its investment narrative. This approval, alongside other innovations like the BIOMAG III trial, signifies Teleflex's shift towards differentiated, higher-value medical devices. However, investors should consider ongoing concerns regarding margin compression, UroLift weakness, and integration risks from the BIOTRONIK Vascular Interventions deal.
Teleflex Incorporated $TFX Shares Sold by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company sold 18,559 shares of Teleflex Incorporated ($TFX) in Q1, reducing its stake by 8.4% to 202,524 shares valued at $24.2 million. Institutional investors and hedge funds collectively own 95.62% of the company. Teleflex currently holds a consensus "Hold" rating from analysts with an average price target of $148.90, and recently traded up 3.3% at $136.72 after exceeding Q1 earnings and revenue expectations.
Teleflex Incorporated $TFX Shares Sold by Sei Investments Co.
Sei Investments Co. significantly reduced its stake in Teleflex Incorporated by 38.9% in the first quarter, selling 46,479 shares and retaining 73,065 shares. Despite this, Teleflex surpassed quarterly earnings and revenue expectations and declared a quarterly dividend of $0.34. Analysts currently hold a "Hold" rating on the stock with a consensus target price of $148.90.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rallied 3.33% to $136.71 on Friday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company's stock closed 2.12% below its 52-week high of $139.67, achieved on April 22nd. This performance occurred on a favorable trading day for the broader stock market.
Needham raises Teleflex stock price target on FDA plasma approval
Needham has increased its price target for Teleflex (NYSE:TFX) to $159 from $147, maintaining a Buy rating, following FDA approval of the company's EZPLAZ Freeze Dried Plasma product. The stock is currently trading at $132.30, and InvestingPro suggests it is undervalued. The approval of EZPLAZ, which offers significant advantages over fresh frozen plasma, is expected to generate $0.07 to $0.09 in earnings per share for every $10 million in sales, with a potential market of $100 million annually.
Needham Raises Price Target on Teleflex to $159 From $147, Keeps Buy Rating
Needham has increased its price target for Teleflex (TFX) to $159 from $147, while maintaining a Buy rating on the stock. This adjustment reflects Needham's continued positive outlook on the company's financial prospects and market position.
Needham raises Teleflex stock price target on FDA plasma approval
Needham has increased its price target for Teleflex (NYSE: TFX) to $159 from $147, maintaining a Buy rating, following FDA approval of its EZPLAZ Freeze Dried Plasma product. The new product offers significant advantages over fresh frozen plasma, particularly for emergency use, due to its easier storage and rapid reconstitution. This approval is expected to contribute $0.07 to $0.09 in EPS for every $10 million in sales.
Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
Teleflex Incorporated announced the FDA Biologics License Application (BLA) approval for its EZPLAZ™ Freeze Dried Plasma (FDP), making it the first FDA-approved freeze-dried plasma product. This product is intended for transfusion in adults with bleeding-related conditions when other plasma products are unavailable, addressing critical needs in both civilian and battlefield settings due to its shelf stability and ease of transport. The approval marks a significant milestone in emergency medicine, developed in partnership with the Defense Health Agency to overcome logistical challenges associated with traditional plasma storage.
Teleflex Incorporated Receives FDA BLA Approval For EZPLAZ Freeze Dried Plasma
Teleflex Incorporated has received FDA Biologics License Application (BLA) approval for its EZPLAZ Freeze Dried Plasma (FDP). This product is the first freeze-dried plasma licensed by the FDA and is intended for adults with bleeding-related conditions requiring plasma coagulation factors, particularly when other plasma products are unavailable. EZPLAZ FDP offers logistical advantages with a 12-month shelf life and quick reconstitution, making it suitable for combat and prehospital settings where traditional plasma products face challenges.
Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
Teleflex Incorporated has received FDA Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP), marking the first FDA-approved freeze-dried plasma product. This approval addresses critical logistical challenges in providing plasma for bleeding-related conditions, especially in emergency and battlefield settings, enabling easier storage and rapid reconstitution. The product was developed in collaboration with the Defense Health Agency to meet mission-critical medical priorities.
Teleflex receives FDA approval for freeze dried plasma product By Investing.com
Teleflex Incorporated announced FDA approval for its EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma product licensed by the FDA. This product is intended for adults with bleeding conditions requiring plasma coagulation factors when other plasma products are unavailable. EZPLAZ FDP offers logistical advantages over
Teleflex Number of Employees 2026 | Employee Count & Headcount Data
Teleflex, Inc. (TFX) had approximately 15,496 employees worldwide as of March 2026, marking a 3.2% growth from 2023. The company, headquartered in Wayne, Pennsylvania, is actively hiring with 295 job postings in 2026, though hiring velocity has declined. Its workforce is primarily concentrated in the United States, and the average employee salary is $75,478.
Irenic Capital Management LP Takes $104.06 Million Position in Teleflex Incorporated $TFX
Irenic Capital Management LP has acquired a new position in Teleflex Incorporated, purchasing 870,000 shares valued at approximately $104.06 million, making it their third-largest holding. This move contributes to Teleflex's high institutional ownership of 95.62%, with other major investors also increasing their stakes. Despite analyst sentiment remaining a "Hold" with a consensus price target of $147.70, Teleflex recently beat quarterly earnings and revenue expectations.
Dimensional Fund Advisors LP Has $119.26 Million Stock Holdings in Teleflex Incorporated $TFX
Dimensional Fund Advisors LP reduced its stake in Teleflex Incorporated by 20.3% in the first quarter, now holding 997,144 shares valued at $119.26 million. Several other institutional investors also adjusted their holdings, with some acquiring new positions and others increasing existing ones. Teleflex reported strong Q1 earnings, beating analyst estimates, and provided FY 2026 guidance, while analysts maintain a "Hold" rating with an average target price of $147.70.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rose 2.40% to $134.20 on Tuesday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.21% and 1.03% respectively. Teleflex Inc. closed 3.92% below its 52-week high.
Investor Relations
Teleflex is a global provider of medical technologies focused on improving health and quality of life through purpose-driven innovation. The company's diverse portfolio includes solutions in various medical fields, and it is known for brands like Arrow, Deknatel, and UroLift. Teleflex encourages investors to stay informed through news, events, and email alerts, emphasizing its commitment to empowering healthcare professionals.
